Termination of Ultragenyx’s UX053 Phase I/II study is a minor setback for mRNA therapeutics:… EP News Bureau May 16, 2023 UX053 was one of five non-vaccine mRNA therapeutics in clinical trial development. The other four are all currently in Phase I/II…
